Table 1. Serious adverse events and ocular treatment-emergent adverse events in the study eye.

Adverse event n (%) of participants with events	SAD			MAD
	0.5 mg (n=3)	2 mg (n=3)	4 mg (n=6)	2 mg (n=6)	4 mg (n=6)
Ocular SAE	0	0	0	0	0
Systemic SAE	0	0	0	1 (16.7)*	0
Ocular TEAE in the study eye	1 (33.3)	0	1 (16.7)	1 (16.7)	2 (33.3)
IOP increased	1 (33.3)	0	0	0	0
Conjunctival haemorrhage	0	0	1 (16.7)	0	0
Allergic conjunctivitis	0	0	0	1 (16.7)	0
Posterior capsular opacification	0	0	0	0	1 (16.7)
Vision acuity decreased	0	0	0	0	1 (16.7)

IOP, intraocular pressure; MAD, multiple ascending dose; SAD, single ascending dose; SAE, serious adverse event; TEAE, treatment-emergent adverse event.